英国首批80万剂疫苗料数天内运抵 卫生大臣称春季疫情会有改善
英国成为首个西方国家批准辉瑞(PFE.US)及BioNTech(BNTX.US)新冠疫苗上市。英国广播公司(BBC)报道,当地监管机构MHRA (Medicines and Healthcare Products Regulatory Agency)表示,该疫苗提供高达95%的保护率,可於下周安全上市,养老院长者等高危人群可在数日内开始接种。
据报英国已订购4,000万剂该疫苗,可供2,000万人接种每人两针,大约1,000万剂疫苗预料可很快供应,其中第一批80万剂将在未来数日内运抵英国。
英国卫生大臣夏国贤表示,有信心到明年春季,疫情将会得到改善。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.